Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Illumina, Qnity Electronics and nVent Electric lead Zacks' latest Strong Buy picks as markets eye inflation, rates and global risks.

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Mid Cap Strategy”. A copy of the Q2 2026 investor letter can be downloaded here. In the quarter, equity markets posted strong returns as resilient economic growth and robust corporate earnings supported investor sentiment, although AI-related companies continued to dominate market […]

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Clinical momentum and NovaSeq X placements drive revenue guidance raise.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

In late July 2026, Illumina reported second-quarter results showing revenue of US$1,159 million versus US$1,059 million a year earlier, while net income eased to US$207 million from US$235 million and diluted earnings per share from continuing operations slipped to US$1.35 from US$1.49. At the same time, the company lifted its 2026 revenue outlook to US$4.60 billion–US$4.64 billion and guided third-quarter revenue of US$1.14 billion–US$1.16 billion, underscoring how clinical sequencing...